<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01376817</url>
  </required_header>
  <id_info>
    <org_study_id>ELomega3</org_study_id>
    <secondary_id>2007-005611-26</secondary_id>
    <nct_id>NCT01376817</nct_id>
  </id_info>
  <brief_title>Comparative Study About the Impact of Two Oil Emulsions Administered Intravenously on Severe Acute Pancreatitis</brief_title>
  <official_title>Comparative Study About the Impact of Two Oil Emulsions, One of Them Formulated With MCT, LCT, Olive Oil and Omega 3 Fatty Acids Versus Another One Formulated With MCT and LCT, Administered Intravenously on Severe Acute Pancreatitis Clinical Evolution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to comparatively assess the potential antiinflammatory effects
      of intravenous lipid emulsions rich in omega 3 polyunsaturated fatty acids and olive oil
      versus intravenous lipid emulsions made exclusively with MCT and LCT on the evolution of
      patients with severe acute pancreatitis during the period in needing artificial nutrition
      support with total parenteral nutrition so unique.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Information recorded in other data elements.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>Day 10</time_frame>
    <description>LTB4, TXB2, PG2, IL-6, alfa-TNF, C-reactive protein (CRP) Day 1 (before treatment), 5 and 10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evolution of the degree of severity of acute severe pancreatitis</measure>
    <time_frame>During the first 72 hours after admission</time_frame>
    <description>At hospital admission: age, BMI, organ failure. Evolution of the degree of severity of acute severe pancreatitis: severity risk factors at the hospital admission (age, BMI, organ failure), pronostic signs of severity during the first 72 hours after admission : APACHE-II, Ranson criteria, serum hematocrit, CT-scan with Balthazar index, CRP.
Day 10: CT-scan with Balthazar index, CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of acute severe pancreatitis</measure>
    <time_frame>Day 10.</time_frame>
    <description>From day 1 to day 10. Complications of acute severe pancreatitis: local complications (necrosis, pseudocyst, abscess, surgery, ERCP), systemic complications (SIRS, sepsis, organ failure, other ones, mortality).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Severe Acute Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Omega 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MCT / LCT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fat emulsion with MCT, LCT, olive oil and omega 3 fatty acids</intervention_name>
    <description>40% of non-protein calories (25-30 kcal/kg/day) of total parenteral nutrition, IV (in the vein), from day 1 to day 10</description>
    <arm_group_label>Omega 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fat emulsion with MCT and LCT</intervention_name>
    <description>40% of non-protein calories (25-30 kcal/kg/day) of total parenteral nutrition, IV (in the vein), from day 1 to day 10</description>
    <arm_group_label>MCT / LCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of acute pancreatitis: characteristic abdominal pain, serum amylase and / or
             lipase &gt;= 3 times the upper limit of normal range, characteristic CT-scan

          -  Criteria of severity of acute pancreatitis diagnosed at &lt;= 72 hours following
             admission: severity Index of Balthazar's CT-scan (with contrast) &gt;= grade D, APACHE-II
             &gt;= 8, C-reactive protein &gt;= 150 mg/L

          -  Inability to initiate feeding (oral or with nutritional supplements) and / or enteral
             nutrition during the 5 days after the diagnosis and prediction of the indication of
             nil-by-mouth &gt;= 5 days

          -  &lt;= 3 mmol/L of triglycerides in the blood

          -  Men and women aged &gt;= 18 years old

          -  Acceptance of informed consent

        Exclusion Criteria:

          -  Known hipersensitivity to the fish, egg or soy proteins

          -  Lipid etiology

          -  &gt; 3 mmol/L of triglycerides in the blood

          -  Severe hepatic impairment

          -  Severe renal insufficiency without dialysis or haemofiltration

          -  Serious disturbances of blood clotting

          -  Acute shock

          -  Infusion therapy general contraindications

          -  Clinical conditions of instability that must not be taken with parenteral nutrition

          -  Have other acute or chronic inflammatory diseases

          -  Status of severe immunosuppression: cytotoxic treatment in 15 days prior to inclusion
             and / or a disease that causes white blood cells levels &lt;5000/mm3

          -  Treatment with steroids &gt; 0.25 mg/kg/day of prednisone or equivalent doses of
             corticosteroids: as pre-treatment and / or during admission
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Cardona Pera, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jordi Virgili Arumí</last_name>
    <phone>00-34-932919050</phone>
    <phone_ext>9303</phone_ext>
    <email>jvirgili@santpau.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordi Virgili Arumí</last_name>
      <phone>00-34-932919050</phone>
      <phone_ext>9303</phone_ext>
      <email>jvirgili@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Daniel Cardona Pera, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amelia Romero Merlos, Bachelor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan María Sánchez Segura, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ferran Caballero Mestres, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manuel Rodríguez Blanco, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vicens Artigas Raventós, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Josefina Muñoz Casadevall, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Antònia Mangues Bafalluy, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.santpau.cat/</url>
    <description>Hospital de la Santa Creu i Sant Pau's website</description>
  </link>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2011</study_first_submitted>
  <study_first_submitted_qc>June 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2011</study_first_posted>
  <last_update_submitted>June 17, 2011</last_update_submitted>
  <last_update_submitted_qc>June 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Daniel Cardona Pera (principal investigator)</name_title>
    <organization>Section of Artificial Nutrition and Intravenous Mixtures, Fharmacy Service, Hospital de la Santa Creu i Sant Pau</organization>
  </responsible_party>
  <keyword>Severe acute pancreatitis</keyword>
  <keyword>total parenteral nutrition</keyword>
  <keyword>fat emulsions</keyword>
  <keyword>omega 3 fatty acids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

